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Background: Peripheral arterial disease is a significant problem worldwide. In developing countries such as India, the
increased incidence of smoking and other forms of nicotine intake has resulted in a large proportion of young individuals
with Buerger’s disease. The results of surgical and endovascular treatment for this condition have not been very
rewarding. Hence, we focused on providing alternative therapies. Neovascularization by autologous bone marrow
mononuclear cell transplantation is being tried as an alternative therapeutic option. We have reviewed our series of
patients who underwent autologous bone marrow mononuclear cell transplantation during the last 2 years.
Methods:We enrolled 38 patients who were chosen to undergo autologous bone marrowmononuclear cell transplantation
for nonreconstructible Buerger’s disease. We injected the bone marrow mononuclear cells into the calf muscles of the
affected limbs in 36 patients. We monitored ulcer healing, ankle-brachial index (ABI), and transcutaneous oximetry
(TcPO2) level.
Results: No procedurally related complications occurred, although one injected sample of bone marrow aspirate later
revealed infestation with Strongyloides stercoralis. Two patients were seropositive on the Venereal Disease Research
Laboratory test and were not injected with the bone marrow mononuclear cells. Three patients (12%) underwent major
amputations<6months. The others had improvements in their ulcer healing, an increase in the mean ABI of 0.14 (range,
0.1-0.19; P < .01), and improvement in the mean TcPO2 of 52 mm Hg (range, 40-68 mm Hg, P < .01), with resultant
limb salvage in all at 6 months. All patients discontinued smoking during the study period.
Conclusions:Use of bonemarrow–derived progenitor cell transplantation into ischemic limbs is a relatively safe procedure
with no demonstrable side effects at 6 months. These study data support conducting controlled and multicenter trials to
evaluate the efficacy of this therapy in preventing amputation in selected patients with Buerger’s disease who have critical
limb ischemia. (J Vasc Surg 2008;48:53S-60S.)Therapeutic angiogenesis represents an attempt to re-
lieve inadequate blood flow by the directed growth and
proliferation of blood vessels. Neovascularization is a com-
plex process involving multiple growth factors, receptors,
extracellular signaling pathways, and local and bone marrow–
derived cells. New blood vessel formation can occur in adult
life as a result of two distinct mechanisms. The first is
angiogenesis,1,2 which involves the proliferation of capillar-
ies and hence an increase in the local blood flow. The
second is arteriogenesis, wherein the already existing high-
resistance collateral vessels increase in size, resulting in a
decrease in resistance and an increase in blood flow to the
ischemic region.3
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doi:10.1016/j.jvs.2008.09.005Angiogenesis occurs under various conditions, includ-
ing local ischemia. Local cellular ischemia is said to affect
the transcription factor hypoxia-inducible factor 1,4 which
in turn leads to expression of vascular endothelial growth
factor (VEGF), fibroblast growth factor (FGF), VEGF
receptors, nitric oxide, and insulin-like growth factors.5
These local changes result in migration of the endothelial
progenitor cells and formation of new thin walled blood
vessels.6-8 The extracellular matrix also plays a role in this
process. The sprouting of capillaries forms a new immature
capillary network. The maturation of these immature cap-
illaries involves the incorporation of pericytes under the
influence of various cytokines and growth factors.9-11
Therapeutic angiogenesis can be induced by the im-
plantation of bone marrow mononuclear cells. Kamihata et
al12 and Shintani et al13 have shown that bone marrow
mononuclear cells contain not only endothelial progenitor
cells but also angiogenic factors and cytokines and that
implantation of bone marrow mononuclear cells into isch-
emic tissues augments collateral vessel formation. Although
CD34 is the most popular marker for stem cell selection for
inducing therapeutic angiogenesis, others such as CD133
stem cells14-16 and CD117 stem cells17 also are important
in therapeutic angiogenesis.
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eral arterial disease due to a large population of diabetic
patients (42 million in 2007) and unabated smoking. Al-
though the exact data are unavailable, 20% to 40% of these
patients are estimated to have Buerger’s disease, also
known as thromboangiitis obliterans, especially in those
who smoke a crude form of rolled tobacco leaves called
beedies or have other forms of tobacco intake, including
chewing of gutka, a highly concentrated form of tobacco
leaves.
A significant social problem in patients with thrombo-
angiitis obliterans is that they are young, most are from
lower socioeconomic strata, and many are single breadwin-
ners for their families and are generally unskilled manual
workers. This socioeconomic problem, coupled with the
fact that present medical, surgical, and endovascular treat-
ment modalities have not been very successful, has resulted
in a dire need for alternative therapies. Thus, investigations
have been initiated of the role of bone marrow–derived
Fig 1. A grid was created over calf muscles and bone marrow
mononuclear cells were injected in 30 to 40 sites.
Fig 2. Strongyloides stercoralis was found in the bone marrow
aspirate of one patient.progenitor cell transplantation into ischemic limbs in thesepatients, in whom loss of a limb could have serious reper-
cussions on the entire family. Various studies have con-
cluded that transplantation of bone marrow mononuclear
cells could contribute to a safe and effective strategy for
achievement of therapeutic angiogenesis and hence preven-
tion of amputation.18,19
MATERIALS AND METHODS
Patients. Thromboangiitis obliterans was diagnosed
by the modified Olin20 criteria and included smoking his-
tory, age of onset45 years, infrapopliteal arterial occlusive
disease, angiographic evidence of medium and small vessel
disease, upper limb involvement or phlebitis migrans, ab-
sence of atherosclerotic risk factors other than smoking/
tobacco use at the time of initial diagnosis, and exclusion of
autoimmune diseases, diabetes mellitus, proximal source of
emboli, and hypercoagulable states.
Inclusion criteria. Our inclusion criteria for patients
qualifying to undergo bone marrow progenitor cells trans-
Table I. A, Descriptive statistics for ankle-brachial index
Variable No. Minimum Maximum Mean SD SE
Baseline 38 0.12 0.47 0.2637 0.06804 0.0111
1 mon 36 0.27 0.60 0.3681 0.06602 0.01100
6 mon 33 0.30 0.65 0.4173 0.06983 0.01216
Table I. B, Paired samples statistics for ankle-brachial
index
Variable Mean SD SEM P
Baseline-1 mon .09861 .03735 .00623 .001
Baseline-6 mon .14636 .02608 .00454 .001
1-6 mon .05030 .02675 .00466 .001
SD, Standard deviation; SE, standard error; SEM, standard error of the mean.
Table II. A, Descriptive statistics transcutaneous
oximetry
Variable N Minimum Maximum Mean SD SE
Baseline 38 20 51 28.18 5.526 .896
1 mon 36 34 60 48.17 6.134 1.022
6 mon 33 40 68 52.12 5.904 1.028
Table II. B, Paired sample test analysis of transcutaneous
oximetry data
Variable Mean SD SEM P
Baseline-1 mon 19.833 5.940 .990 .001
Baseline-6 mon 23.697 6.307 1.098 .001
1-6 mon 3.424 3.666 .638 .001
SD, Standard deviation; SE, standard error; SEM, standard error of the mean.plantation, as approved by Ethics Committee for Human
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sent, were age45 years, no history of diabetes mellitus, no
evidence of malignancy, patients with Buerger’s disease, has
limb-threatening ischemia, and established methods of
treatment were not possible or were tried and were not
successful.
Exclusion criteria. Patients with diabetes mellitus, ath-
erosclerosis, thrombotic disease, proximal embolic source,
malignancy, or hypercoagulable states were excluded. Those
who would require amputation proximal to transmetatarsal
level were also excluded.
Procedures. The study enrolled 38 men (38 limbs)
with thromboangiitis obliterans. Patients’ mean age was 34
years. All 38 patients had nonhealing ischemic wounds of a
minimum of 2 months’ duration that showed no improve-
ment with conventional therapy. All patients also had rest
pain of 2 months’ duration.
The baseline evaluation for all patients included a com-
plete blood count, erythrocyte sedimentation rate, blood
Fig 3. This patient had severe hand ischemia with nonrecon-
structible thromboangiitis obliterans.
Table III. A, Descriptive statistics for the visual analog
scale
Variable N Minimum Maximum Mean SD SE
Baseline 38 8 10 8.74 .724 .117
1 mon 36 1 5 3.36 1.046 .174
6 mon 33 0 4 2.45 1.660 .289
Table III. B, Paired samples test analysis of the visual
analog scale results
Variable Mean SD SEM P
Baseline-1 mon 5.361 1.222 .204 0.001
Baseline-6 mon 6.242 1.696 .295 0.001
1-6 mon .879 1.139 .198 0.001
SD, Standard deviation; SE, standard error; SEM, standard error of the mean.glucose level, renal and liver function tests, an electrocar-diogram, and a chest radiograph. An echocardiogram and
tests for connective tissue disorders and hypercoagulable
states were not done routinely due to financial constraints
in these patients.
An epidural catheter was placed on admission in all
patients (except one with upper limb ischemia) for pain
control. All were counseled against smoking. Appropriate
wound care was commenced and they were prescribed
systemic antibiotics. Intra-arterial digital substraction an-
giography was done for the indexed extremity before the
patient was diagnosed as having nonreconstructible disease.
The primary outcome was limb salvage at 6 months.
We looked for decrease in rest pain, healing of ulcers,
improvements in the ankle-brachial index (ABI) scores, and
rise in transcutaneous oxygen pressure (TcPO2) levels in the
patients undergoing bone marrow progenitor cell trans-
plantation.
Regional anesthesia was used for the procedure. To
increase the yield, bone marrow was aspirated from the
posterior iliac crests in different directions using a bone
marrow aspiration needle and 20-mL syringes.The average
Fig 4. A, Toe amputation site after failed vascular reconstruction
and B, 5 weeks after therapy.volume of bone marrow aspirated was 400 mL, with min-
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collection was done in a sterile container.
The marrow was taken to the sterile stem cell process-
ing laboratory where stem cell enrichment took place in
cyclic guanosine monophosphate conditions. Mainly, the
procedure consisted of red blood cell (RBC) sedimentation
by 6% hydroxyethyl starch (HAES) at unit gravity. This
resulted in RBC depletion of 90%. The nucleated cells
present in the supernatant were concentrated by centrifu-
gation at 1500 rpm. The nucleated cell pellet was reconsti-
tuted in sterile 6% HAES, and 0.5 mL of cell suspension was
taken for cell count viability and CD34 count by flow
cytometry.
After RBC depletion and volume reduction, the nucle-
ated cell count was 5.8  107  4  107/mL. The final
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Fig 5. A, Representation of the mean ankle-brachial ind
subject data for the ankle-brachial index.volume of the RBC-depleted cell suspension was 45 to 60mL, which was used for injections into the patient. The
total number of CD34 in the cell suspension was 9.8 
9.91 106. Viability was 99%. CD34 count was done using
BD Procount (Becton Dickinson, Franklin Lakes, NJ) us-
ing International Society of Hematotherapy and Graft En-
gineering protocol.
The cell suspension was cultured and found to be free
of contamination in 36 patients. This was then injected into
multiple sites in the gastrocnemius muscle of the ischemic
lower limb. The sites marked on the gastrocnemius muscle
were 1 cm apart. A 2-mL syringe and a 20-gauge needle
were used to inject 0.75 mL into each site intramuscularly
(Fig 1). A baseline ABI and TcPO2 were performed preop-
eratively.
We followed up the patients weekly for 4 weeks and
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JOURNAL OF VASCULAR SURGERY
Volume 48, Number 6S Motukuru et al 57Sin rest pain, ABI and TcPO2 was done at the end of 1 month
and 6 months. We judged an increase in ABI of0.1 as an
improvement according to the standard assessment of in-
terventional therapy for peripheral arterial diseases.21
TcPO2 was measured on the dorsum of the foot using a
TCM400 TcPO2 monitoring system (Radiometer Medical
APS, Denmark). This report includes 38 patients recruited
between November 2005 and 2007. Two bone marrow
aspirates were seropositive on the Venereal Disease Re-
search Laboratory test, although the initial test results were
negative, and hence were not processed. Three patients
required amputation by the 6-month follow-up, which left
33 patients in the study. In addition, one patient was found
to have Strongyloides stercoralis (Fig 2) in the collection,
which we came to know a day after the therapy.
Statistical analysis. The study data were analyzed us-
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Fig 6. A, Representation of visual analog scale data and
data on the visual analog scale.ing SPSS 16.0 software (SPSS Inc, Chicago, Ill). Statisticalanalysis has been provided for baseline, 1 month, and 6
months for ABI (Table I), TcPO2 (Table II), and visual
analog scale scores (Table III). The difference in the base-
line and end of study has been compared using the paired-
samples t-test. The level of significance was fixed at P .05.
RESULTS
We tested the ABI in all study patients before the
procedure and also obtained a follow-up ABI measurement
in all the patients at 4 weeks and 6 months after the
procedure. The ABI improved in all 33 patients (Fig 5).
The mean preprocedural ABI was 0.26 (range, 0.12-0.47).
An increase in ABI of 0.1 at the end of 1 month and 6
months was noted in 33 patients, with a mean increase of
0.14.
Similarly, TcPO2 was measured before the procedure
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increase in TcPO2 levels from the mean baseline TcPO2 of
28 mm Hg (range, 20-51 mm Hg). The mean TcPO2 level
was 48 mm Hg (range, 34-60 mm Hg) at 4 weeks after the
procedure and 52 mm Hg (range, 40-68 mm Hg) at the
end of 6 months (Fig 7).
Marrow implantation induced no local inflammatory
reaction in the form of redness, pain, erythema, or swelling
in any of the study participants. No major adverse events
were reported in any of the patients during their hospital
stay or in the 6-month follow-up period.
We used bone marrow mononuclear cells containing
CD34 cells, and it is postulated that these cell fractions
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Fig 7. A, Representation of mean transcutaneous oxim
individual subject data for transcutaneous oximetry levelrelease multiple angiogenic factors to enhance angiogenesisin addition to supplying endothelial progenitor cells. The
mean (SD) CD34 count was 9.88  9.91 million (range,
1.62-33.6 million), the total mean mononuclear cell count
(108) was 26.23  17.98 (range, 1.80-64.93), and the
mononuclear cell count per mL (107) was 0.3 to 14.4.
Clinical improvement was shown by decrease in rest
pain on a visual analog scale score in 25 patients, with
complete regression in eight (Fig 6). Also, ulcer healing was
noted in 23 patients, and seven patients had complete
healing of their ulcer in a time frame of 1 to 6 months. In
three patients the size of the ulcer did not change during
the study period. Improvement in rest pain, ulcer healing,
ABI, and TcPO2 levels were maintained in all patients
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rest pain with progression of foot gangrene.
DISCUSSION
We have shown that implantation of bone marrow–
derived progenitor cells into the ischemic limbs resulted in
an increase in blood flow in the ischemic limbs in 33
patients. This was assessed by documenting an increase in
the ABI and in the TcPO2 measurements. Rest pain also
decreased in most patients. Similarly on follow-up, we also
noted an improved ulcer healing and that seven of the
ulcers completely healed (Figs 3 and 4).
Chronic critical limb ischemia is defined as persistent
recurring rest pain of 2 weeks’ duration not responding
to regular, adequate analgesia and an ankle pressure of50
mm Hg or a toe pressure of 30 mm Hg. The study
inclusion criteria were that we enroll patients with Buerg-
er’s disease who did not have diabetes and had undergone
or were unable to undergo the standard treatment options
for their disease. All of the 38 patients in our study had
critical limb ischemia despite having undergone earlier
surgical treatment in the form of lumbar sympathectomy
before they were included in the study.
Angiogenesis1,22,23 that occurs can result in growth of
new capillaries or growth of pre-existing collateral vessels.
For newly formed vessels to survive, they must undergo
remodeling and acquire a layer of smooth muscle cells. In
view of the complex process of vessel formation, treatments
that use only one angiogenic factor might result in subop-
timal endothelial channels.
The CD34 fraction in bone marrow mononuclear cells
reportedly synthesized not only angiogenic growth factors
like VEGF and basic FGF but also angiopoietin I,9 which is
important in the maturation and maintenance of the vascu-
lar system; hence, resulting in blood vessels with an ade-
quate composition of smooth muscle cells, periendothelial
matrix, and pericytes.24
Buerger’s disease, also known as thromboangiitis oblit-
erans, is characterized by the occurrence of segmental
thrombotic occlusions of the medium- and small-sized
arteries. This entity is seen in young smokers with no other
risk factors and is more common in Asia than in the West.
The incidence of major amputation in this patient popula-
tion according to multiple studies is 12% to 31% and has
included both patients with claudication and those with
critical limb ischemia.25
Because this is probably the first study of this kind in
India in patients with ischemic limbs, and also owing to the
small number of patients included in the study, the inter-
pretation of the results, which appear promising, are lim-
ited. Absence of a control, the small number of patients
enrolled, and absence of a postprocedural angiogram are
the limitations of this study. A point to be remembered in
this discussion is that most of the patients belong to lower
socioeconomic strata and are single breadwinners for their
families. This procedure, which was done in 36, revealed no
adverse effects on any of them and more important, the
approximate cost of the total procedure and stay in thehospital was US $200 to $300 compared with peripheral
vascular bypass, which would cost approximately US $1000
to $1300. Because these patients belonged to a low-income
group, with out any medical insurance, their care was
completely funded.
Another factor to be kept in mind is that although all
the patients in the study said they did not restart smoking
during their 6 month follow-up, no testing for urine coti-
nine by radioimmunoassay was done. Hence, the contribu-
tion of persistent smoking to the disease outcome could not
be assessed. We would also like to state in conclusion that
this study is a preliminary one to show safety, but that
efficacy requires a placebo-controlled study, because other
associated treatment, namely smoking cessation, could
have substantially influenced the outcome.
We acknowledge Ms Rohini Nilekeni of Arghyam
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Dr Henrik Sillesen (Copenhagen, Denmark). This issue has
been controversial for many years, and in our part of the world, this
is not an option. We just heard from Australia that they are working
on the Tamaris project, which is just another option of treatment
for these patients who cannot be reconstructed. Would it be
possible to do a double-blind trial? I can easily imagine some
problems with how to have a placebo injection, but would it be
possible?
Dr Vishnu Motukuru. That would be tough. The TAG
study was published, we have the first part of the study; it was a
double-blind plan in which one group had saline injected and the
other had stem cells injected. But in the immune setup, it is not
going to be easy. The second thing you need to bear in mind is the
whole cost of this procedure, it is probably around $200 to $300,
and even this had to be funded in total.
Dr Krish Soundararajan (Philadelphia, Pa). In an era where
surgeons seek invasive therapy, it is refreshing to see your work on
nonsurgical management of critical limb ischemia. I have two
questions. The first one is would the stem cell therapy have any
different outcome if you had applied it in ischemia due to athero-
sclerosis rather than Buerger’s disease? Is there any reason why you
chose to confine the therapy to Buerger’s disease?
The second question is with regards to the cost factor and my
understanding that many patients in India may not be able to
afford therapies to improve lifestyle in occlusive disease. How do
you see stem cell therapy helping an average laborer in India?
Would this be a technology which is beyond their means?
DrMotukuru. Firstly, it is still quite controversial. So we just
wanted to apply this, because it is being done for the first time in
India, so we wanted to play safe. So that is the reason we excluded
diabetics and we offered this only to patients in whom nothing else
is possible. Probably in our older patients and patients with ath-
erosclerosis, there are other alternatives which can be tried. But this
was offered only to a specific subset of nonclassical Buerger’s in
whom everything else has been tried. So that is the reason we
specifically selected this subset wherein there is no option at all
other than an amputation.
Dr Soundararajan. Does that mean if you had a patient with
ischemia due to atherosclerosis who did not have any other optionsDr Motukuru. I doubt it, because we were basically looking
at people who are young, who are extremely healthy, and who
could probably tolerate any complication. So a person with ad-
vanced atherosclerosis, your morbidity/mortality would go up
given the nature of the disease.
Dr Chris Liapis (Athens, Greece). Most of the times patients
with Buerger’s disease have lesions in the distal arteries, like digital
arteries. Why do you think that injecting the calf area is going to
improve the situation in the obstructed distal arteries?
DrMotukuru. Because this was the first series, we injected all
the patients into the calf muscles. But the last five cases, we were
also injecting the stem cells into the foot. But because we don’t
have a 6-month follow-up, I haven’t presented those.
Dr Enrico Ascher (Brooklyn, NY). I know of at least three
stem cell studies investigating the potential for limb salvage. In our
study we agreed to inject the stem cells along the course of tibial
vessels. Do you think that this method better promotes angiogen-
esis?
Dr Motukuru. I am not aware of it, sir. But we started
injecting in the foot. But as far as the results are concerned, I have
no idea.
Dr Gregorio Sicard (St. Louis, Mo). These patients, obvi-
ously, all of them are very heavy smokers. And did you look, even
though it is a small number of patients, how many of these patients
continued their smoking habits? Because I think that is going to
muddy the results.
And the second question, one of the therapies that is being
looked at, obviously, in multiple institutions across the world, is
rather than obtaining the stem cells from the bone marrow is to use
granulocyte stimulation factors or certain factors that promote the
recruitment of stem cells from the bone marrow to the site of the
ischemia. Have you looked at that in India?
DrMotukuru. We haven’t, sir, because there were a couple of
papers which said granulocyte-stimulated factors helped, but then
there were a couple of papers that said it doesn’t help. And
secondly, one of the limitations of the study was we did give them
a strong counseling, but we did not do urine creatinine assay levels
to really assess whether they were actually smoking or not smoking;
and hence, we couldn’t really assess the impact of our counseling
on the results, purely because of financial constraints.
